Vestipitant
Overview[edit | edit source]
Vestipitant is a selective neurokinin-1 receptor (NK1R) antagonist that has been investigated for its potential therapeutic effects in treating various conditions such as nausea, vomiting, and anxiety disorders. It is a member of the class of drugs known as substance P antagonists, which work by blocking the action of substance P, a neuropeptide involved in the transmission of pain and other sensory signals.
Chemical Structure[edit | edit source]
Vestipitant has a complex chemical structure that allows it to selectively bind to the NK1 receptor, inhibiting its activity. The molecular formula of Vestipitant is C23H21F6N3O, and it is characterized by the presence of multiple fluorine atoms, which contribute to its high affinity for the receptor.
Mechanism of Action[edit | edit source]
Vestipitant functions by competitively inhibiting the binding of substance P to the NK1 receptor. This receptor is predominantly found in the central nervous system and is involved in the regulation of emesis, pain, and stress response. By blocking this receptor, Vestipitant can reduce the symptoms associated with excessive activation of the NK1 pathway.
Clinical Applications[edit | edit source]
Vestipitant has been studied for its potential use in treating:
- Chemotherapy-induced nausea and vomiting (CINV)
- Postoperative nausea and vomiting (PONV)
- Anxiety disorders
Although promising in preclinical studies, the clinical development of Vestipitant has faced challenges, and it is not currently approved for use in any major market.
Pharmacokinetics[edit | edit source]
Vestipitant is administered orally and is absorbed into the bloodstream, where it reaches peak plasma concentrations within a few hours. It is metabolized primarily in the liver and excreted through the urinary system. The drug has a half-life that allows for once-daily dosing in clinical settings.
Safety and Tolerability[edit | edit source]
In clinical trials, Vestipitant has been generally well-tolerated, with a safety profile similar to other NK1 receptor antagonists. Common side effects include mild headache, dizziness, and fatigue.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
